152 related articles for article (PubMed ID: 20087154)
1. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.
Goicoechea M; Jain S; Bi L; Kemper C; Daar ES; Diamond C; Ha B; Flaherty J; Sun S; Richman D; Louie S; Haubrich R;
AIDS; 2010 Mar; 24(5):707-16. PubMed ID: 20087154
[TBL] [Abstract][Full Text] [Related]
2. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
[TBL] [Abstract][Full Text] [Related]
3. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
Hawkins T; Veikley W; St Claire RL; Guyer B; Clark N; Kearney BP
J Acquir Immune Defic Syndr; 2005 Aug; 39(4):406-11. PubMed ID: 16010161
[TBL] [Abstract][Full Text] [Related]
4. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
Hawkins T; Veikley W; Durand-Gasselin L; Babusis D; Reddy YS; Flaherty JF; Ray AS
Antimicrob Agents Chemother; 2011 Apr; 55(4):1549-55. PubMed ID: 21282432
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078
[TBL] [Abstract][Full Text] [Related]
6. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W
J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
[TBL] [Abstract][Full Text] [Related]
8. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155
[TBL] [Abstract][Full Text] [Related]
9. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
Baheti G; King JR; Acosta EP; Fletcher CV
AIDS; 2013 Jan; 27(2):221-5. PubMed ID: 23032419
[TBL] [Abstract][Full Text] [Related]
10. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
[TBL] [Abstract][Full Text] [Related]
11. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW
Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
[TBL] [Abstract][Full Text] [Related]
13. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
Duwal S; Schütte C; von Kleist M
PLoS One; 2012; 7(7):e40382. PubMed ID: 22808148
[TBL] [Abstract][Full Text] [Related]
15. Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
[TBL] [Abstract][Full Text] [Related]
16. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
Ray AS; Myrick F; Vela JE; Olson LY; Eisenberg EJ; Borroto-Esodo K; Miller MD; Fridland A
Antivir Ther; 2005; 10(3):451-7. PubMed ID: 15918336
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
[TBL] [Abstract][Full Text] [Related]
19. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).
Hirt D; Ekouévi DK; Pruvost A; Urien S; Arrivé E; Blanche S; Avit D; Amani-Bosse C; Nyati M; Legote S; Ek ML; Say L; McIntyre J; Dabis F; Tréluyer JM
Antimicrob Agents Chemother; 2011 Jun; 55(6):2961-7. PubMed ID: 21464249
[TBL] [Abstract][Full Text] [Related]
20. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
